

Remarks

Claims 1-41 were pending. Due to the restriction requirement, and in order to simplify prosecution, claims 4, 6, 9-13, 15-24, 29-30, 32-36 and 40-41 are cancelled without prejudice to prosecution in a future application. Claims 42-48 were added. Therefore, claims 1-3, 5, 7-8, 14, 25-28, 31, 37-39, and 42-48 are now pending.

Claims 1, 2, 5, 7-8, 25-28, and 31 were amended to clarify the claims, for example to simply prosecution of the present application. SEQ ID NOS: 18 should be examined in the same application as SEQ ID NOS: 6 and 19 because SEQ ID NOS: 6 and 19 are fragments of SEQ ID NO: 18.

Although FGF-5 expression in tumor cell lines and tissue samples was previously observed, none of these publications disclosed the use of FGF-5 as an immune target for cancer immunotherapies. The inventors have determined for the first time that FGF-5 expression in neoplasms, such as renal cell carcinomas, is correlated with the immunogenicity of FGF-5. Therefore, the claims are directed to methods of treating an FGF-5 expressing neoplasm by stimulating an immune response to FGF-5, for example by administering an immunogenic FGF-5 peptide fragment.

Support for the amendment to claim 1 can be found throughout the specification, for example page 1, lines 5-6.

Claims 7 and 14 were amended due to the cancellation of claim 6. Claim 25 was amended to correct the dependency.

Support for the new claims can be found throughout the specification, for example:

Claims 42- 43: page 4, lines 23-24.

Claim 44: page 4, lines 19-22.

Claims 45-47: page 26, lines 18-20.


Claim 48: page 26, lines 2-3.

No claim amendments were made to distinguish prior art. No new matter is added by this amendment.

If there are any questions regarding this amendment, the examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446